Current Neuro-Oncology

Volume 28 Number 3
31 January 2026

Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 3, 31 January

Kashiwagi H, Wanibuchi M, Ikeda N, Nonoguchi N, Furuse M, Kawabata S, Nihei K, Hu N, Akita K, Ono K, Miyatake SI.
Investigator-led clinical trial of boron neutron capture therapy system for recurrent high-grade meningiomas after radiation therapy: Randomized phase II study.
Neuro Oncol. 2026 Jan 21:noaf279. doi: 10.1093/neuonc/noaf279. PMID: 41560342. Interventional study˰ ˍ

Patel SH, Mayorov S, Kim W, Singh K, Loftus JR, Patrie JT, Batchala PP, Ko A, Lee MD, Jain R, Schiff D.
Magnetic resonance imaging features differentiate histologic and molecular subtypes of glioblastoma IDH-Wild type CNS WHO grade 4.
J Neurooncol. 2026 Jan 21;176(3):177. doi: 10.1007/s11060-026-05431-8. PMID: 41563605. Observational study. ˍ

Nielsen SH, Tabari S, Skjøth-Rasmussen J, Jensdottir M, Urup T, Hansen AE, Bartek J, Rasmussen R.
Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study.
Acta Neurochir (Wien). 2026 Jan 23;168(1):22. doi: 10.1007/s00701-026-06771-0. PMID: 41575548. Observational study. ˍ

Teo T, Karanjia J, Wabnitz P, Kichenadasse G, Gan HK, Cooper A, Fuller D, Noll B, Zhou Y, Wei L, Wang H, Liu J, Zhou X, Wang K, Wang S.
A phase I/IIa study of auceliciclib in patients with advanced solid tumours and in combination with temozolomide in patients with recurrent/relapsed high-grade glioma.
ESMO Open. 2026 Jan 24;11(2):106035. doi: 10.1016/j.esmoop.2025.106035. PMID: 41581338. Interventional study. ˍ

Peng F, Koh WY, Lee CY.
Frontal glioblastoma masquerading as schizophrenia exacerbation.
Oxf Med Case Reports. 2026 Jan 25;2026(1):omaf291. doi: 10.1093/omcr/omaf291. PMID: 41589101. Case report. ˍ

Slater JM, Horick NK, Nachtigall LB, Parsons MW, Tritos NA, Faje AT, Dietrich J, Fullerton B, Sherman JC, Curry WT, Arrillaga-Romany IC, Cahill DP, Nahed BV, Wang IS, Botticello TM, Oh KS, Yeap BY, Shih HA.
Cognitive Function, Quality of Life, and Survival Outcomes in Patients with Lower Grade Gliomas Treated with Proton Radiation Therapy: A Phase II study.
Neuro Oncol. 2026 Jan 25:noag008. doi: 10.1093/neuonc/noag008. PMID: 41581137. Interventional study˰ ˍ

Piha-Paul SA, De La Fuente M, Iwamoto F, Zhu JJ, Nagpal S, Braiteh F, Chandra S, Fu Y, Chen C, Yang Z, Tsai KK.
Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.
ESMO Open. 2026 Jan 27;11(2):106047. doi: 10.1016/j.esmoop.2025.106047. PMID: 41604813. Interventional study. ˍ

Singh J, Bhardwaj S, Singh S, Mansoori S, Vasant S, Srivastava K, Kedia S, Garg A, Suri A, Sharma MC, Sarkar C, Suri V.
Pediatric and Adolescent/Young Adult High-Grade Gliomas With Adult-Type Molecular Features.
Pathol Int. 2026 Jan 27;76(1):e70087. doi: 10.1111/pin.70087. PMID: 41589343. Observational study˰ ˍ

Dipasquale A, Giordano P, Bosio A, Wijnenga MMJ, Giordano L, Losurdo A, Persico P, Padovan M, Viggiano A, Catapano G, Geurts M, Pessina F, Santoro A, Lombardi G, Simonelli M.
Reasons driving choice and clinical course of patients with CNS WHO grade 3 IDH mutant glioma receiving vorasidenib after surgery: a pilot experience.
J Neurooncol. 2026 Jan 28;176(3):186. doi: 10.1007/s11060-026-05439-0. PMID: 41604034. Observational study˰ ˍ

Dixit KS, Kumthekar P, Lukas RV, Williams A, Tate MC, Chandler JP, Jamshidi P, Helenowski I, Zhang H, Bloch O, Raizer JJ.
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.
J Neurooncol. 2026 Jan 28;176(3):185. doi: 10.1007/s11060-026-05446-1. PMID: 41604000. Interventional study˰ ˍ

Ene CI, Singh S, Venkataraman T, Phillips LM, Long JP, Singh D, Tran ND, Tufaro F, Anand PJ, Navin N, Prabhu S, Weinberg JS, Larman HB, Gomez-Manzano C, Fueyo J, Lang FF.
Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET).
Clin Cancer Res. 2026 Jan 29. doi: 10.1158/1078-0432.CCR-25-3566. PMID: 41609523. Interventional study˰ ˍ

Jia Z, Jiang T, Zhang Y, Chen Q, Di Z, Yuan Q, Qian K, Gan L, Ma C, Lin X.
Clinical Efficacy and Safety Assessment of Specific-Mode Electroacupuncture Stimulation Combined With Paclitaxel for Recurrent Malignant Gliomas: Study Protocol for a Single-Arm Trial.
JMIR Res Protoc. 2026 Jan 29;15:e84593. doi: 10.2196/84593. PMID: 41610368. Interventional study protocol. ˍ

Sener U, Galloway T, Neth B, Uhm J, Kizilbash SH, Campian JL, Caron S, Breen WG, Lehrer E, Golembiewski E, Schultz S, Hughes H, Steinmetz S, Geyer S, Mead-Harvey C, Huebert C, Tauer W, Mason C, Burns TC, Pritchett J, Haddad T.
Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy.
Contemp Clin Trials Commun. 2025 Dec 23;49:101593. doi: 10.1016/j.conctc.2025.101593. PMID: 41567708. Interventional study protocol. ˍ

Neuro-Oncology Clinical Research Program; Camphausen K.
Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response After Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or Gliosarcoma.
medRxiv [Preprint]. 2025 Dec 30:2025.12.23.25342908. doi: 10.64898/2025.12.23.25342908. PMID: 41607658. Interventional study. ˍ

Makimoto A, Terashima K, Nishikawa R, Fujisaki H, Kurihara J, Ihara S, Adachi JI, Enokizono M, Mori N, Morikawa Y, Yuza Y.
Safety and Efficacy of Tumor-Treating Fields (TTFields) Therapy for Pediatric High-Grade Glioma: Results of a Prespecified Interim Analysis of the First Three Cases.
Children (Basel). 2026 Jan 6;13(1):84. doi: 10.3390/children13010084. PMID: 41597092. Interventional study. ˍ

Gao M, Chen Q, Zhang H, Tian Y, Fu Z, Yan M, Liu C.
Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis.
Front Pharmacol. 2026 Jan 13;16:1705451. doi: 10.3389/fphar.2025.1705451. PMID: 41608019. Observational study. ˍ

Çelebi A, Yıldırım B, Yıldırım E, Işık S, Çoban E, Bıyıklı E, Köstek O, Bayoğlu İV, Sarı M.
Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach.
Brain Sci. 2026 Jan 16;16(1):97. doi: 10.3390/brainsci16010097. PMID: 41594818. Case report. ˍ